Anti-myeloma activity of pamidronate in vivo.
Two patients with progressive myeloma were treated with pamidronate disodium every 2-4 weeks. Pamidronate therapy resulted in a significant reduction of marrow plasmacytosis and plasma cell labelling index (PCLI), together with durable (> or = 20 months) stabilization of immunoglobulin (Ig) levels and an increase in bone mineral density in the first patient and > 50%, reduction in Ig levels and bone marrow plasmacytosis in the second. This, to our knowledge, is the first report of an anti-myeloma effect of bisphosphonates in humans and provides evidence that a therapeutic intervention largely directed at the myeloma microenvironment may alter the natural history of the disease.
Dhodapkar
M V
MV
Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, USA.
Singh
J
J
Mehta
J
J
Fassas
A
A
Desikan
K R
KR
Perlman
M
M
Munshi
N C
NC
Barlogie
B
B
D000368:Aged; D001853:Bone Marrow / Q000473:pathology; D004164:Diphosphonates / Q000627:therapeutic use*; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology; D000077268:Pamidronate; D010950:Plasma Cells / Q000473:pathology
D004164:Diphosphonates; D007074:Immunoglobulin G; D000077268:Pamidronate